深圳微芯生物科技股份有限公司 前次募集资金使用情况报告的鉴证报告 KPMG Huazhen LLP 8th Floor, KPMG Tower Oriental Plaza 1 East Chang An Avenue Beijing 100738 China Telephone +86 (10) 8508 5000 Fax +86 (10) 8518 5111 Internet kpmg.com/cn 毕马威华振会计师事务所 (特殊普通合伙) 中国北京 东长安街 1 号 东方广场毕马威大楼 8 层 邮政编码:100738 电话 +86 (10) 8508 5000 传真 +86 (10) 8518 5111 网址 kpmg.com/cn 关于深圳微芯生物科技股份有限公司 前次募集资金使用情况报告的鉴证报告 毕马威华振专字第 2504538 号 深圳微芯生物科技股份有限公司董事会： 我们接受委托，对后附的深圳微芯生物科技股份有限公司 (以下简称"微芯生物") 于 2022 年 7 月通过发行可转换公司债券募集的资金 (以下简称"募集资金") 截至 2025 年 6 月 30 日 止的使用情况报告 (以下简称" ...

Group 1 - The 21st Summer Annual Meeting of the Yabuli Entrepreneur Forum took place in Guangzhou on September 12-13, 2025, focusing on the theme "Forging Ahead Steadily - Corporate Development in the New Global Context" [1] - The chairman and general manager of Microchip Biotech, Lu Xianping, stated that Chinese biopharmaceutical companies have established high-level technological barriers, which he considers to be among the best in the domestic industry [1] - The innovative drug industry has seen significant market capitalization growth this year, with some leading companies doubling their market value, indicating a rising recognition of Chinese innovative drug companies' R&D capabilities globally [1] Group 2 - Despite the optimistic outlook, Lu Xianping acknowledged that the industry faces challenges, particularly the need for reasonable profit support to drive innovation as companies approach the critical 0 to 1 stage [1] - The core issue for future industry development is to overcome key technologies, including AI computing power, special algorithms, big data modeling capabilities, and original research [1]

Core Viewpoint - The 21st Summer Annual Meeting of the Yabuli Entrepreneur Forum in 2025 focused on the theme "Forging Ahead Steadily - Corporate Development in the New Global Context" [1] Industry Insights - Chinese biopharmaceutical companies have established high-level technological barriers, with some leaders in the industry being recognized for their R&D capabilities globally [3] - The market capitalization of the innovative drug industry has seen significant growth this year, with some leading companies doubling their market value [3] - The investment community is increasingly focusing on the value of the biopharmaceutical industry, positively impacting the healthy development of the industry ecosystem [3] Challenges - The industry faces challenges as innovators approach the critical 0 to 1 stage, where opportunity costs increase, necessitating reasonable profit support for innovation [3] - The optimization of the healthcare system is crucial; successful reforms could elevate biopharmaceuticals to a significant sector within the national economy [3] Future Development - The core issue for future industry development lies in overcoming key technologies, including AI computing power, special algorithms, big data modeling capabilities, and original research [3] - A lack of original research could hinder progress, especially in the face of potential time constraints [3]

Investment Rating - The report maintains an "Overweight" rating for the innovative drug sector, indicating that the industry is expected to outperform the overall market [5][11]. Core Insights - The report emphasizes the long-term investment value of Chinese innovative drugs, highlighting three main supporting logics: innovation upgrades, profitability inflection points, and normalization of outbound business development (BD) [5]. - Chinese biotech companies are demonstrating significant capabilities in global innovation, with notable products emerging in the PD-1/VEGF dual antibody and EGFR/c-MET dual antibody ADC categories [5]. - Leading biotech firms like BeiGene and Innovent Biologics are projected to reach profitability in 2025, suggesting a sustained high growth trajectory for the sector [5]. - The total value of license-out agreements from mainland China to Europe and the US has reached $94.3 billion as of September 2025, significantly surpassing the $51.9 billion recorded for the entirety of 2024 [5]. Summary by Sections Industry Overview - The report discusses the potential impact of a proposed US government draft that aims to limit American pharmaceutical companies from acquiring experimental drugs from China, although the likelihood of this draft being implemented is considered low [5]. - The report argues that even if the US tightens regulations, Chinese biotech can still pursue collaborations with European firms and establish overseas companies to navigate these restrictions [5]. Company Valuations - The report includes a valuation table for key companies in the pharmaceutical and biotech sector, detailing market capitalization, earnings per share (EPS) projections, and price-to-earnings (PE) ratios for 2024 to 2027 [6]. - Notable companies mentioned include: - Hengrui Medicine with a market cap of 453.3 billion yuan and a projected PE ratio of 68.3 for 2024 [6]. - BeiGene with a market cap of 436.5 billion yuan, expected to turn profitable by 2026 [6]. - Innovent Biologics and other firms are also highlighted for their growth potential and market performance [6].

Group 1 - Sichuan Road and Bridge's controlling shareholder plans to reduce its stake by up to 2% of the company's total shares, amounting to approximately 174 million shares [1] - Jinlongyu's shareholder terminates the share transfer agreement, halting the planned transfer of 5.32% of the company's shares [1] - Doli Technology's subsidiary plans to establish a joint venture in Spain with an investment of approximately 505 million yuan, with a 70% stake held by Doli Technology [1][2] Group 2 - Chongqing Pharmaceutical, a subsidiary of Zhongyao Holdings, has received approval for clinical trials of its drug, Clopidogrel Hydrochloride Tablets [3][4] - Dongyangguang plans to jointly increase capital in a subsidiary to acquire 100% of Qinhuai Data China for 28 billion yuan [5] - Kangzhi Pharmaceutical's controlling shareholder intends to transfer 5.0004% of the company's shares at a price of 5.34 yuan per share, totaling approximately 122 million yuan [6] Group 3 - Huali Co., Ltd. announces two shareholders plan to reduce their stakes by a combined total of up to 3.96% of the company's shares [7] - Fangbang Co., Ltd.'s director plans to reduce his stake by up to 15,000 shares, representing 0.1844% of the total shares [8] - China Pacific Insurance suggests issuing HKD-denominated convertible bonds, with proceeds aimed at supporting its main insurance business and strategic initiatives [9] Group 4 - Microchip Biotech's shareholder plans to reduce its stake by up to 3% of the company's total shares [10] - Hongbai New Materials' controlling shareholder intends to reduce its stake by up to 3% due to funding needs [11] - Zhejiang Rongtai clarifies that its sales in the robotics components sector are minimal and will not significantly impact annual net profit [12] Group 5 - ST Tianmao voluntarily withdraws its application for A-share listing, which has been accepted by the Shenzhen Stock Exchange [13] - Qingxin Environment's shareholder plans to reduce its stake by up to 1% of the company's total shares [14] - Lanjik Technology's two shareholders plan to reduce their stakes by a combined total of up to 2% of the company's shares [15] Group 6 - BYD's executives and core personnel collectively increased their holdings in the company by approximately 52.33 million yuan [16] - Trina Solar's subsidiary signs contracts for the sale of 2.48 GWh of energy storage products, marking a significant overseas order [17] - Chutianlong's shareholder plans to reduce its stake by up to 3% of the company's total shares [18] Group 7 - Zhongjuxin's shareholder plans to reduce its stake by up to 2.5% of the company's total shares due to funding needs [19] - ST Hezhong's controlling shareholder is under bail pending trial, but company operations remain unaffected [20] - Shoukai Co., Ltd. reports a signed contract amount of 973 million yuan for August, with cumulative contracts of 13.15 billion yuan for the year [21] Group 8 - Jucheng Co., Ltd.'s shareholder plans to reduce its stake by up to 2.61% of the company's total shares due to personal funding needs [22]

Core Viewpoint - Micron Biomedical (688321.SH) experienced a significant drop in stock price, reaching a new low since July 4, 2023, with a decline of 9.58% to 30.28 yuan [1] Company Actions - Bio-Ocean plans to reduce its holdings in Micron Biomedical by a maximum of 12,233,893 shares, which represents up to 3% of the company's total share capital, through a combination of centralized bidding and block trading within six months after 15 trading days from the announcement date [1]

Group 1 - The major shareholder, Bio-Ocean Biological Group Co., Ltd., holds 34,705,162 shares of Microchip Biotech Co., Ltd., accounting for 8.51% of the total share capital [2] - Bio-Ocean plans to reduce its holdings by up to 12,233,893 shares, which is no more than 3% of the total share capital, within six months starting from 15 trading days after the announcement [3] - The reduction will be executed through a combination of centralized bidding and block trading, with specific limits on the number of shares that can be sold in any 90-day period [3] Group 2 - The reduction plan is driven by strategic funding needs and will not significantly impact the company's governance structure or ongoing operations [6] - The company will adjust the number of shares to be reduced in case of any corporate actions such as dividends or stock splits during the reduction period [3] - The selling price will be determined based on market conditions and will comply with relevant regulations [3]

Group 1 - Tianpu Co., Ltd. experienced a significant stock price increase of 185.29% from August 22 to September 10, leading to a halt for further investigation due to abnormal trading [4] - Baiyin Nonferrous Metals has been investigated by the China Securities Regulatory Commission for suspected violations of information disclosure [5] - Qingshan Paper Industry confirmed that its production and operational activities are normal, with no significant changes in daily operations [6] Group 2 - Aoyang Health announced that its stock will continue to be suspended due to ongoing negotiations regarding a share transfer by its controlling shareholder [7] - ST Jinke will implement a capital reserve transfer to increase share capital, resulting in a one-day stock suspension [8] - ST Haofeng's stock will resume trading on September 11 after a share transfer agreement was signed, making Zhixin Network the controlling shareholder [9] Group 3 - Fushun Special Steel's stock will be suspended for one day due to a tender offer for shares by Ningbo Meishan Free Trade Port Zone Jincheng Shazhou Equity Investment Co., Ltd. [10] - Fuliwang's subsidiary plans to invest 500 million yuan in a high-end wire material research and production project [11] - ST Tianmao's application for voluntary delisting has been accepted by the Shenzhen Stock Exchange [12] Group 4 - Dongyangguang plans to jointly increase capital in a subsidiary for the acquisition of Qinhuai Data China [13] - Betta Pharmaceuticals intends to issue H-shares and apply for listing on the Hong Kong Stock Exchange [14] - Longzi Co., Ltd. plans to acquire a 67.5% stake in Chongqing Time for approximately 92.475 million yuan [15] Group 5 - Dongfang Guoxin plans to establish a joint venture for a technology company with Shunyi Jin Kong [16] - ST Lianshi signed a pre-restructuring investment agreement with selected investors [18] - Shaanxi Construction Group won four construction projects worth over 5 billion yuan in August [19] Group 6 - Dema Technology won a smart logistics project with a well-known Latin American e-commerce giant, valued at approximately 290 million yuan [20] - Mongolian Grass Ecology's subsidiary led a consortium to win a 225 million yuan ecological restoration project [21] - Dajin Heavy Industry signed a long-term production agreement for offshore wind power foundations, with a total value of about 1.25 billion yuan [24] Group 7 - Zhendong Medical's controlling shareholder plans to transfer 5% of the company's shares [25] - ST Hezhong's controlling shareholder is under bail pending trial, but company operations remain unaffected [26] - BYD's senior management and core personnel collectively increased their holdings by approximately 52.33 million yuan [27] Group 8 - Jiahe Meikang's shareholder plans to reduce its stake by up to 1.94% [28] - Sichuan Road and Bridge's controlling shareholder plans to reduce its stake by up to 2% [30] - Lanke Technology's shareholders plan to reduce their holdings by up to 2% [31]

Group 1 - Hualing Steel's shareholder, Xintai Life, has recently increased its stake by 69.0862 million shares and plans to continue increasing its holdings by 1% to 2% [1] - Jingfang Technology's shareholder has terminated its share reduction plan ahead of schedule, with no shares sold during the period [1] - Huali Co., Ltd. plans to reduce its holdings by no more than 3.96% of the company's shares [1] Group 2 - Various companies, including Wuchan Jinlun, Changhua Chemical, COFCO Technology, and Jieshun Technology, have announced plans to reduce their holdings by no more than 3% of their shares [1] - Other companies such as Micron Biotech, Hongbai New Materials, and Jucheng Technology have also indicated plans to reduce their stakes by varying percentages, mostly around 2% to 3% [1] - Specific reductions include 2.61% by Jucheng Co., 2.5% by Zhongju Xinxin, and 1.94% by Jiahe Meikang [1]

Group 1 - The core point of the article is that Shenzhen Microchip Biotech Co., Ltd. announced a planned share reduction by its major shareholder, BGI Group, due to strategic funding needs [1] - BGI Group currently holds approximately 34.71 million shares of Microchip Biotech, representing 8.51% of the total share capital [1] - BGI Group intends to reduce its holdings by up to approximately 12.23 million shares within six months, utilizing both centralized bidding and block trading methods [1] Group 2 - The revenue composition for Microchip Biotech in 2024 is projected to be 97.96% from the pharmaceutical manufacturing industry and 2.04% from other businesses [1] - As of the announcement, Microchip Biotech has a market capitalization of 13.7 billion yuan [1]